Skip to main content

Generics

  • Watson confirms patent challenge for generic Combigan

    MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

  • Mylan closes Bioniche acquisition

    PITTSBURGH Generic drug maker Mylan has managed to snag Bioniche Pharma Holdings sooner than expected, Mylan said Tuesday. Mylan had announced its plans to buy Bioniche for $550 million in July.

     

  • Actavis' generic Strattera gets OK from FDA

    MORRISTOWN, N.J. The Food and Drug Administration has approved a generic drug made by Actavis for treating attention deficit hyperactivity disorder, Actavis said Wednesday.

     

    The FDA approved the drug maker’s atomoxetine hydrochloride capsules in the 10-mg, 18-mg, 25-mg, 40-mg, 60-mg, 80-mg and 100-mg strengths. The drug is a generic version of Eli Lilly’s Strattera, which had $532 million in sales during the 12-month period ended in June, according to IMS Health.

     

     

  • Teva markets AcuDial generic

    NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.

     

    The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.

     

     

  • FDA approves Sun's generic Strattera

    MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

    Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

    Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

  • Salix settles MoviPrep patent dispute with Novel

    RALEIGH, N.C. Salix Pharmaceuticals announced its agreement with Novel Labs to settle its patent litigation over Novel’s proposed generic version of MoviPrep.

     

  • Sigmapharm files ANDA for generic Hepsera

    FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

    FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

  • IMS Health exec to NACDS conference attendees: Expect opportunities, uncertainties for drug market

    SAN DIEGO The U.S. drug market will present opportunities as well as uncertainties over the next decade, according to remarks made by IMS Health VP industry relations Doug Long at the National Association of Chain Drug Stores’ 2010 Pharmacy and Technology Conference held here on Monday.

     

X
This ad will auto-close in 10 seconds